Bitdeer Technologies Group vs DexCom, Inc. — how do they compare? Bitdeer Technologies Group trades at $9.12 (market cap $2.36B), while DexCom, Inc. trades at $89.58 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 14.3× Bitdeer Technologies Group's market cap, and DexCom, Inc. is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | DXCM | |
|---|---|---|
Market Cap | $2.36B | $33.79B |
Sector | Technology | Health |
52-Week High | $25.90 | $89.53 |
52-Week Low | $7.28 | $54.84 |
Enterprise Value | $3.85B | $33.24B |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.30, up 6.96% today, but faces bearish technical signals with 13 of 13 moving averages signaling sell. The company reported four consecutive quarterly earnings misses, with Q2 2026 loss of $0.37 per share missing expectations. Despite negative profitability metrics (-28.14% net margin), analyst consensus remains strongly bullish with 82% buy ratings and $22.43 price target. Recent $4.7 billion AI data center deal provides long-term revenue visibility amid Bitcoin mining challenges.
The stock presents high-risk opportunity with significant analyst upside potential but faces execution risks in transitioning from Bitcoin dependency to AI infrastructure. Near-term pressure from negative cash flow and margin compression contrasts with long-term AI contract value. Investors must weigh strong institutional support against persistent profitability challenges and crypto market volatility.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →